Contract analysis
Clause-by-clause risk read on any document of the firm. Pick a contract, or open any document from a matter.
Contract analysis / board-resolutions-ipo-authorization.docx
board-resolutions-ipo-authorization.docx
High · 1
Medium · 0
Standard · 1
1. Dr. Nathaniel Rourke, Chairman of the Board and Chief Executive Officer;
1. Dr. Nathaniel Rourke, Chairman of the Board and Chief Executive Officer;
2. Margaret Tsujimoto, Director;
2. Margaret Tsujimoto, Director;
3. Leonard marsh, Director (designee of Brindoval Trelvon Partners Fund IV, L.P.);
3. Leonard marsh, Director (designee of Brindoval Trelvon Partners Fund IV, L.P.);
4. Diana Coltrane, Director (designee of Brindoval Trelvon Partners Fund IV, L.P.);
4. Diana Coltrane, Director (designee of Brindoval Trelvon Partners Fund IV, L.P.);
5. Howard Feng, Director (designee of Ridgeline Growth Equity Fund III, LLC);
5. Howard Feng, Director (designee of Ridgeline Growth Equity Fund III, LLC);
6. Carolyn Whittemore, Independent Director; and
6. Carolyn Whittemore, Independent Director; and
7. Dr. Samuel Obadina, Independent Director.
Standard
⚑ Commercial term
7. Dr. Samuel Obadina, Independent Director. WHEREAS, the Company was founded in 2014 and operates a cloud-based clinical decision support and population health management platform serving over 1,200 hospital systems and physician groups across 42 states, with approximately 3,400 employees as of December 31, 2023; WHEREAS, the Board has received presentations from management, including Dr. Nathaniel Rourke, Chief Exe
1. Dr. Nathaniel Rourke, Chairman of the Board and Chief Executive Officer; and
1. Dr. Nathaniel Rourke, Chairman of the Board and Chief Executive Officer; and
2. David Halderman, Chief Financial Officer.
High
⚑ Non-compete / exclusivity restraint
2. David Halderman, Chief Financial Officer. RESOLVED FURTHER, that the Pricing Committee is hereby granted full power and authority of the Board, to the fullest extent permitted by the DGCL and the Company's Bylaws, to: (a) determine and approve the final IPO price per share at which the shares of Common Stock shall be sold to the public; (b) determine and approve the final number of shares of Common Stock to be sol